Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)

NCT05544552 is registered in ClinicalTrials.gov with Tyra Biosciences, Inc as lead sponsor.

NCT NCT05544552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05544552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)
Lead sponsor
Tyra Biosciences, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 22, 2022
Completion date
June 30, 2027
Enrollment
310 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, advanced urothelial carcinoma, bladder cancer, fgfr3 gene alteration, fgfr3 gene mutation, locally advanced urothelial carcinoma, metastatic urothelial carcinoma, non-muscle-invasive bladder cancer, solid tumor, solid tumor, adult, urinary tract cancer, urinary tract carcinoma, urinary tract tumor, urothelial carcinoma